{"id":"NCT01991821","sponsor":"Acacia Pharma Ltd","briefTitle":"European Phase III Study of APD421 in PONV","officialTitle":"Randomised, Double-blind, Placebo-controlled Phase III Study of APD421 (Amisulpride for IV Injection) as Prophylaxis Against Post-operative Nausea and Vomiting","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-07","primaryCompletion":"2014-01","completion":"2014-01","firstPosted":"2013-11-25","resultsPosted":"2019-08-02","lastUpdate":"2019-08-20"},"enrollment":368,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["PONV"],"interventions":[{"type":"DRUG","name":"APD421","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"APD421","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A comparison of the efficacy of APD421 and placebo in the prevention of PONV in patients at moderate-to-high risk of PONV.","primaryOutcome":{"measure":"Complete Response (no Emesis, Significant Nausea or Rescue Medication)","timeFrame":"24 hours after end of surgery","effectByArm":[{"arm":"APD421","deltaMin":95,"sd":null},{"arm":"Placebo","deltaMin":83,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.093"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":2,"countries":["France","Germany"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":169},"commonTop":["Procedural Pain","Nausea","Flatulence","Constipation","Hypotension"]}}